

**TaiGen Biopharmaceuticals Holdings Limited**

**太景醫藥研發控股股份有限公司**

**Notification for the Annual General Meeting of Year 2025**

**2025 年股東常會開會通知書**

I. Date of Announcement : April 22, 2025

發文日期：2025 年 4 月 22 日

II. Convener : The Board of Directors of TaiGen Biopharmaceuticals Holdings Limited

召集人：太景醫藥研發控股股份有限公司 董事會

III. To : All shareholders

受文者：全體股東

IV. Date of Annual Shareholders Meeting : 10:00 am., Wednesday, May 23, 2025

開會日期：2025 年 5 月 23 日(星期三)上午 10 時整

V. Venue : B1., No. 28, Ln. 420, Sec. 5, Chenggong Rd., Neihu Dist., Taipei City , Taiwan (R.O.C.)

開會地點：台北市內湖區成功路五段 420 巷 28 號 B1

VI. Attendees : Hsieh-Chang Li (CPA, Deloitte)

列席：勤業眾信會計師事務所 李協昌會計師

VII. Share transfer recordation suspension period : From March 25, 2025 to May 23, 2025

股票停止過戶期間：2025 年 3 月 25 日至 2025 年 5 月 23 日

VIII. Agenda 會議主要內容：

1. Report Items 報告事項

(1) 2024 Business Report.

2024年度營業報告

(2) 2024 Audit Committee's Review Report to the Financial Statement.

審計委員會2024年度決算表冊之審查報告

(3) 2024 Directors' Remuneration

2024年度董事酬金報告

2. Ratification Items 承認事項

(1) To Ratify the 2024 Financial Statements and Business Report. (Ordinary Resolution)

2024年度財務報表暨營業報告書(普通決議)

(2) To Ratify the surplus earnings distribution Proposal. (Ordinary Resolution)

2024年度盈餘分配案(普通決議)

3. Proposed Resolutions And Directors Election 討論及選舉事項

- (1) To elect the 8th Board of Directors including 6 Directors and 3 Independent Directors.

本公司第八屆董事六席及獨立董事三席選舉案

- (2) To relieve the non-competition restriction to the newly elected Directors. (Supermajority Resolution)

本公司新任董事及其代表人解除競業禁止之限制案(重度決議)


- (3) To revised the AMENDMENTS AND RESTATED RESTATED MEMORANDUM OF ASSOCIATION. (Special Resolution)

本公司「公司章程」部分條文修正案(特別決議)

4. Motions 臨時動議

5. Meeting adjourned 散會

By Order of the Board

  
Chairman 董事長: Philip Huang 黃國龍

Kindly schedule your time to attend the annual general meeting. If you are unable to attend and intend to give your proxy to another person, please sign or chop the proxy form and fill in the proxy's name and address, and then deliver the completed proxy form to the Company at least five days (no later than May 16, 2025) prior to the annual general meeting. Designated representative from the institutional investor has to bring the Power of Attorney signed and/or chopped when attending the annual general meeting.

至希 察照撥冗出席，如本人不克出席欲委託代理人出席，請於委託書上蓋章或簽名，並填妥代理人姓名、地址後於開會五日前(至遲於 2025 年 5 月 16 日)送(寄)達本公司。法人股東指派代表人出席時請出具簽名或用印之指派書。

Contact person 聯絡人: Tel: 886-2-8177-7020 Ext # 1716 吳先生 (Andy Wu)  
Email: [andywu@taigenbiotech.com](mailto:andywu@taigenbiotech.com)